1. Home
  2. MTD vs BIIB Comparison

MTD vs BIIB Comparison

Compare MTD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mettler-Toledo International Inc.

MTD

Mettler-Toledo International Inc.

HOLD

Current Price

$1,431.49

Market Cap

28.8B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$173.27

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTD
BIIB
Founded
1991
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8B
24.2B
IPO Year
1997
1991

Fundamental Metrics

Financial Performance
Metric
MTD
BIIB
Price
$1,431.49
$173.27
Analyst Decision
Buy
Buy
Analyst Count
12
23
Target Price
$1,423.33
$179.48
AVG Volume (30 Days)
119.8K
1.5M
Earning Date
02-05-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
8.22
N/A
EPS
40.11
10.97
Revenue
$3,941,791,000.00
$10,065,900,000.00
Revenue This Year
$4.30
$3.56
Revenue Next Year
$4.73
N/A
P/E Ratio
$35.55
$15.77
Revenue Growth
4.77
4.77
52 Week Low
$946.69
$110.04
52 Week High
$1,525.17
$190.20

Technical Indicators

Market Signals
Indicator
MTD
BIIB
Relative Strength Index (RSI) 48.01 48.70
Support Level $1,392.16 $170.04
Resistance Level $1,456.75 $175.29
Average True Range (ATR) 37.48 5.47
MACD -6.54 -0.69
Stochastic Oscillator 30.83 43.41

Price Performance

Historical Comparison
MTD
BIIB

About MTD Mettler-Toledo International Inc.

Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 28%, China about 16% and the rest of the world about 19%.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: